Insmed INSM

Nasdaq 100Nasdaq 100

Jump To Section

    $

    9
    8
    7
    6
    5
    4
    3
    2
    1
    0
    0
    9
    8
    7
    6
    5
    4
    3
    2
    1
    0
    0
    .
    9
    8
    7
    6
    5
    4
    3
    2
    1
    0
    0
    9
    8
    7
    6
    5
    4
    3
    2
    1
    0
    0
    9
    8
    7
    6
    5
    4
    3
    2
    1
    0
    0
    -$9.57 (-5.44%)Past DayToday's Volume:
    9
    8
    7
    6
    5
    4
    3
    2
    1
    0
    0
    9
    8
    7
    6
    5
    4
    3
    2
    1
    0
    0
    9
    8
    7
    6
    5
    4
    3
    2
    1
    0
    0
    ,
    9
    8
    7
    6
    5
    4
    3
    2
    1
    0
    0
    9
    8
    7
    6
    5
    4
    3
    2
    1
    0
    0
    9
    8
    7
    6
    5
    4
    3
    2
    1
    0
    0
    ,
    9
    8
    7
    6
    5
    4
    3
    2
    1
    0
    0

    Relative Strength Index (RSI)

    - The Relative Strength Index (RSI) is a momentum oscillator that measures the speed and change of price movements. It is typically used to identify overbought or oversold conditions in financial markets.

    - The RSI is calculated using the following formula:

    RSI = 100 - (100 / (1 + RS))

    Where RS is the ratio of the average gains to the average losses over a specified period.

    - The default time period used is 14 days.

    - RSI values range between 0 and 100.

    RSI values above 70 are considered overbought (indicating a potentially opportune time to sell)

    RSI values below 30 are considered oversold (indicating a potentially opportune time to buy)

    RSI is not a perfect indicator and should be used in conjunction with other technical analysis tools, this is for informational purposes only and is not a substitute for professional financial advice.

    About

    Insmed (INSM) Business Model and Operations Summary
    Insmed Incorporated, a biopharmaceutical company, develops and commercializes therapies for patients with serious and rare diseases. The company offers ARIKAYCE for the treatment of Mycobacterium avium complex lung disease as part of a combination antibacterial drug regimen for adult patients. It is also developing Brensocatib, an oral reversible inhibitor of dipeptidyl peptidase 1 for the treatment of patients with bronchiectasis and other neutrophil-mediated diseases; and Treprostinil Palmitil Inhalation Powder, an inhaled formulation of a treprostinil prodrug treprostinil palmitil for the treatment of pulmonary arterial hypertension and other rare pulmonary disorders. Insmed Incorporated was founded in 1988 and is headquartered in Bridgewater, New Jersey.

    Key Insights

    Insmed (INSM) Stock Information & Key Business Metrics

    • Market Cap

      $19.30 Billion

    • Average Daily Volume

      3,282,956 Shares

    • 52-Week Range

      $60.40-$106.83

    • Free Cash Flow

      -$906.14 Million

    • Total Outstanding Shares

      213.27 Million Shares

    • Free Float

      208.99 Million Shares (98.9% Outstanding)

    • CEO

      William H. Lewis

    • Total Employees

      1,271

    • Current Dividend

      No dividend

    • IPO Date

      June 1, 2000

    • Headquarters

      700 Us Highway 202/206, Bridgewater, NJ, 08807

    Financial Highlights

    Insmed (INSM) Key Financial Metrics

    Earnings Reports

    Expected vs. Actual Quarterly Earnings-Per-Share & Revenue

    Short Volume

    Daily short volume activity identifies short-term trading pressure and potential price volatility

    Short Interest

    Bi-monthly short interest levels can be used to gauge bearish market sentiment and short squeeze potential

    Revenue Breakdown

    Distribution of revenue across unique business segments & geographies

    Cash Flow Statement

    Income Statement

    Balance Sheet

    Historical Stock Splits

    If you bought 10 shares of INSM before March 3, 2011, you'd have 1 share today

    Historical Dividends

    INSM does not currently pay dividends

    Recent Headlines From The Web

    Latest news, press releases, and media coverage about INSM from trusted financial sources

    Related Companies

    Publicly traded companies similar to Insmed (INSM)
    Boost your savings and earn 3.95% APY with a Marcus by Goldman Sachs savings account, a rate that's 8x the national averagewhen signing up with Financhle. No fees, no minimum deposits, backed by the financial expertise of Goldman Sachs. Terms apply.

    Compete

    The Daily FinanchleSPY Prediction

    Explore

    Live Market OverviewS&P 500 SPYNasdaq 100 QQQRussell 2000 IWMUnusual Options ActivityPrediction Markets

    Research

    News ArticlesEarnings CalendarIPO Calendar & DirectoryAll Tickers

    Financhle

    Login / Sign UpPro SubscriptionAbout UsCareersTerms & ConditionsPrivacy & Cookies Info

    â“’ 2026 Financhle LLC. All Rights Reserved.